Thalidomide Dosing for Intractable Cough in Adults

Evidence for Thalidomide in Intractable Cough

Thalidomide has demonstrated significant efficacy in treating intractable cough, particularly in patients with idiopathic pulmonary fibrosis (IPF), with statistically significant improvements in cough-related quality of life measures 1, 2
The American College of Chest Physicians (ACCP) guidelines suggest thalidomide be considered specifically in patients with IPF and chronic cough where alternative causes have been ruled out, though this recommendation did not achieve consensus among the expert panel 1, 3

Thalidomide has a concerning side effect profile, including its well-known teratogenicity, requiring strict precautions in women of childbearing potential 1, 2
In clinical trials, significantly more patients receiving thalidomide reported adverse events compared to placebo (77% vs 22%; P = .001) 1, 2
Dose reduction may be necessary in some patients (required in 3 of 23 patients in the key trial) 1, 2

Thalidomide should be considered for intractable cough only after ruling out and treating other potential causes of cough 1, 3
Thalidomide should be positioned as a later-line option after trying first-line and second-line options, such as gabapentin therapy, multimodality speech pathology therapy, and low-dose controlled-release morphine 4

Regular monitoring for adverse events is essential during thalidomide treatment 1, 2
Assess response to treatment after 2 weeks to determine if dose escalation from 50 mg to 100 mg daily is warranted 1
Consider dose reduction if side effects are intolerable but cough improvement is observed 1, 2

Thalidomide may have a role in treating cough through anti-inflammatory mechanisms and possibly reduced cough sensory nerve activity 7
For patients with lung cancer experiencing intractable cough, thalidomide is suggested as an option when other approaches have failed, using an N-of-1 trial approach 5, 6